A New Hybrid Phase I-II-III Clinical Trial Paradigm
Frontiers in Biostatistics Seminar Tuesday September 15, 2020 at 1:00PM Eastern Time Peter F. Thall, PhD Department of Biostatistics University of Texas M.D. Anderson Cancer Center Abstract: Conventional evaluation of a new drug, 𝐴, is done in three phases. Phase I relies on toxicity to determine a “maximum tolerable dose” (MTD) of 𝐴, in phase […]